Jun 03, 2020
New First-in-Class Phase 3 TREMFYA® (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52
Apr 06, 2020
The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis
Nov 13, 2019
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace
Nov 11, 2019
TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Oct 12, 2019
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
Sep 23, 2019
International Council Of Dermatologists Introduces New Method Of Determining Psoriasis Severity
Jun 14, 2019
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA(TM) (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
Jun 11, 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Apr 16, 2019
Patient Advocates Applaud Filing of the 'Safe Step Act' in U.S. House of Representatives
Mar 26, 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Feb 28, 2019
Ortho Dermatologics To Present New Analyses At The American Academy Of Dermatology Annual Meeting
Feb 27, 2019
Sun Pharmaceutical Industries Inc. Announces Plans to Present 19 Data Abstracts on ILUMYA(TM) for Moderate-to-Severe Plaque Psoriasis at American Academy of Dermatology 2019 Annual Meeting
Dec 12, 2018
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
Oct 08, 2018
Bausch Health's BRYHALI(TM)(halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Oct 02, 2018
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Efficacy And Safety Data On Bryhali(TM)* (Halobetasol Propionate) Lotion, 0.01% In The Journal Of Drugs In Dermatology
Sep 12, 2018
ECHT-EVAL 2018 - The German Project Implementing the WHO 'Global Report on Psoriasis'
Sep 10, 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis
Aug 13, 2018
Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board
Jul 24, 2018
Unlike Beauty, Psoriasis More Than Skin Deep
Jun 19, 2018
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis